Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients
The use of novel oral anticoagulants in patients with impaired renal function or undergoing immunosuppressive therapy is limited due to the risk of drug-to-drug interactions and anticoagulation-related adverse events. This article aims to assess the current data on the safety of direct-acting oral a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Transplantology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-3943/3/3/22 |
| _version_ | 1797481748704002048 |
|---|---|
| author | Mikołaj Młyński Mikołaj Sajek Zbigniew Heleniak Alicja Dębska-Ślizień |
| author_facet | Mikołaj Młyński Mikołaj Sajek Zbigniew Heleniak Alicja Dębska-Ślizień |
| author_sort | Mikołaj Młyński |
| collection | DOAJ |
| description | The use of novel oral anticoagulants in patients with impaired renal function or undergoing immunosuppressive therapy is limited due to the risk of drug-to-drug interactions and anticoagulation-related adverse events. This article aims to assess the current data on the safety of direct-acting oral anticoagulant-based therapy in the population of kidney transplant recipients and patients with impaired renal function. The most important factors affecting the safety of treatment are the incidence of bleeding events, thromboembolic events, deaths and drug-to-drug interactions. The available data were compared to the findings on warfarin-based anticoagulation. Findings on the use of novel oral anticoagulants in kidney transplant recipients are limited yet promising in terms of safety and efficacy of use. However, current recommendations state that the co-administration of non-vitamin K antagonist oral anticoagulants with several immunosuppressive agents is contraindicated. |
| first_indexed | 2024-03-09T22:18:57Z |
| format | Article |
| id | doaj.art-271e75cebf0841abbe5e625490d95d82 |
| institution | Directory Open Access Journal |
| issn | 2673-3943 |
| language | English |
| last_indexed | 2024-03-09T22:18:57Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Transplantology |
| spelling | doaj.art-271e75cebf0841abbe5e625490d95d822023-11-23T19:17:21ZengMDPI AGTransplantology2673-39432022-06-013320821810.3390/transplantology3030022Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant RecipientsMikołaj Młyński0Mikołaj Sajek1Zbigniew Heleniak2Alicja Dębska-Ślizień3Medical Faculty, Medical University of Gdańsk, 80-210 Gdańsk, PolandMedical Faculty, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, 80-210 Gdańsk, PolandDepartment of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, 80-210 Gdańsk, PolandThe use of novel oral anticoagulants in patients with impaired renal function or undergoing immunosuppressive therapy is limited due to the risk of drug-to-drug interactions and anticoagulation-related adverse events. This article aims to assess the current data on the safety of direct-acting oral anticoagulant-based therapy in the population of kidney transplant recipients and patients with impaired renal function. The most important factors affecting the safety of treatment are the incidence of bleeding events, thromboembolic events, deaths and drug-to-drug interactions. The available data were compared to the findings on warfarin-based anticoagulation. Findings on the use of novel oral anticoagulants in kidney transplant recipients are limited yet promising in terms of safety and efficacy of use. However, current recommendations state that the co-administration of non-vitamin K antagonist oral anticoagulants with several immunosuppressive agents is contraindicated.https://www.mdpi.com/2673-3943/3/3/22chronic kidney diseasekidney transplant recipientanticoagulationnovel oral anticoagulants |
| spellingShingle | Mikołaj Młyński Mikołaj Sajek Zbigniew Heleniak Alicja Dębska-Ślizień Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients Transplantology chronic kidney disease kidney transplant recipient anticoagulation novel oral anticoagulants |
| title | Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients |
| title_full | Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients |
| title_fullStr | Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients |
| title_full_unstemmed | Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients |
| title_short | Safety of Non-Vitamin K Antagonist Oral Anticoagulant Treatment in Patients with Chronic Kidney Disease and Kidney Transplant Recipients |
| title_sort | safety of non vitamin k antagonist oral anticoagulant treatment in patients with chronic kidney disease and kidney transplant recipients |
| topic | chronic kidney disease kidney transplant recipient anticoagulation novel oral anticoagulants |
| url | https://www.mdpi.com/2673-3943/3/3/22 |
| work_keys_str_mv | AT mikołajmłynski safetyofnonvitaminkantagonistoralanticoagulanttreatmentinpatientswithchronickidneydiseaseandkidneytransplantrecipients AT mikołajsajek safetyofnonvitaminkantagonistoralanticoagulanttreatmentinpatientswithchronickidneydiseaseandkidneytransplantrecipients AT zbigniewheleniak safetyofnonvitaminkantagonistoralanticoagulanttreatmentinpatientswithchronickidneydiseaseandkidneytransplantrecipients AT alicjadebskaslizien safetyofnonvitaminkantagonistoralanticoagulanttreatmentinpatientswithchronickidneydiseaseandkidneytransplantrecipients |